Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 310Squamous Cell Carcinoma of Head and Neck 163Head and Neck Neoplasms 145Carcinoma, Non-Small-Cell Lung 97Colonic Neoplasms 89Rectal Neoplasms 81Neoplasm Metastasis 70Neoplasms 59Pancreatic Neoplasms 40Carcinoma, Squamous Cell 38Lung Neoplasms 35Esophageal Neoplasms 25Breast Neoplasms 22Stomach Neoplasms 20Recurrence 20Laryngeal Neoplasms 17Carcinoma 17Tongue Neoplasms 16Mouth Neoplasms 16Esophageal Squamous Cell Carcinoma 14Oropharyngeal Neoplasms 13Salivary Gland Neoplasms 12Adenocarcinoma Of Esophagus 12Hypopharyngeal Neoplasms 11Laryngeal Diseases 10Adenocarcinoma of Lung 10Uterine Cervical Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 9Ovarian Neoplasms 9Nasopharyngeal Carcinoma 9

Interventions

Mitoxantrone 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Androgen-independent Prostate Cancer × Cetuximab × Clear all
NCT00661492 2016-12-09

Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)

US Oncology Research

Phase 2 Completed
115 enrolled 16 charts
Genitourinary

Androgen-independent Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡